Omaha, N.E. (ABC News) — “If he had come to us any later, his heart would have just stopped,” Dr. John Um, Surgical Director of Heart Transplantation at Nebraska Medical…
Determined organ donor – Mmegi Online
Mmegi OnlineDetermined organ donorMmegi OnlineSpeaking to Mmegi in an interview just before he left, Bevan Asekeng said that he believed he was going to learn a lot from the workshop."I believe that when I come back to Botswana, I will have learnt…
Boston Scientific Launches Drug Eluting Stent Solution to Treat Severe Lesions … – Businessweek
Boston Scientific Launches Drug Eluting Stent Solution to Treat Severe Lesions …BusinessweekBoston Scientific has launched in European countries the PROMUS ELEMENT(TM) PLUS BTK (Below The Knee) Everolimus-Eluting Stent System for the treatment of cer…
Persistence pays out exercise benefits in heart failure – News-Medical.net
Persistence pays out exercise benefits in heart failureNews-Medical.netBy Eleanor McDermid, Senior medwireNews Reporter. Health benefits derived from regular exercise accumulate over the long term, shows a 10-year study in patients with heart failure (…
Report: Ohio nurse didn't realize she discarded kidney
A nurse who accidentally disposed of a living donor's kidney during a transplant said she didn't realize it was in chilled, protective slush that she removed from an operating room, took down a hall to a dirty utility room and "flushed dow…
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant …
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS for post-transplant …
Astellas Submits U.S. New Drug Application for Tacrolimus Extended Release … – Sacramento Bee
Astellas Submits U.S. New Drug Application for Tacrolimus Extended Release …Sacramento BeeDeveloped by Astellas, tacrolimus extended release capsules are a once daily formulation of calcineurin-inhibitor immunosuppressant tacrolimus. The NDA submissi…
Barfi's success is humbling; response was unexpected: Basu – Moneycontrol.com
IBTimes IndiaBarfi's success is humbling; response was unexpected: BasuMoneycontrol.com… Basu's latest film Barfi has charmed both filmgoers and critics alike. Combining modern outlook and cinematic aesthetics with a traditional Indian sensib…
Cell Therapeutics' phase 1 study of pacritinib shows encouraging anti-tumour … – pharmabiz.com
Cell Therapeutics' phase 1 study of pacritinib shows encouraging anti-tumour …pharmabiz.comPatients had relapsed following a median of five prior therapies (range 2-15); 44% had failed prior stem cell transplant and 52% were rituximab refractory….
Astellas seeks FDA approval for tacrolimus tablets – Pharmaceutical Business Review
Astellas seeks FDA approval for tacrolimus tabletsPharmaceutical Business ReviewAstellas Pharma US has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the…